Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

We are both speculating because we do not have data from the trial yet,but the Lancet study should be similar to the Brilacidin for Covid in many ways.

https://www.thelancet.com/action/showFullTableHTML?isHtml=true&tableId=tbl1&pii=S1473-3099%2821%2900485-0

From the Lancet study you can see general trends which should be similar to the brilacidin for covid study:

Average age was about..... 64

Males were more affected than females..... greater than 2 to 1

Coexisting conditions ....73 percent had 1 to 3 coexisting medical problems

Take another look at the numbers from the Lancet trial:

Obesity 278 (34%) 138 (34%) 140 (34%)
Chronic cardiac disease 229 (28%) 111 (27%) 118 (28%)
Diabetes 217 (26%) 104 (26%) 113 (27%)
Chronic pulmonary disease 146 (18%) 71 (17%) 75 (18%)
Chronic kidney disease stage 1 to 3 51 (6%) 19 (5%) 32 (8%)
Auto-inflammatory disease 41 (5%) 17 (4%) 24 (6%)
Malignant haemopathy 35 (5%) 16 (4%) 19 (5%)
Chronic neurological disorder including dementia 34 (4%) 18 (4%) 16 (4%)
Mild liver disease 30 (4%) 15 (4%) 15 (4%)
Active malignant neoplasm 28 (3%) 13 (3%) 15 (4%)
Transplantation 11 (1%) 2 (<1%) 9 (2%)
Asplenia 4 (<1%) 1 (<1%) 3 (1%)
AIDS/HIV not on ART

Those are obviously serious coexisting conditions.

It is clear patients with significant but stable medical problems were included in the Lancet trial.

Another point is the coexisting conditions in the predominantly Russian study population should be much higher in the western Europeans in the Lancet study. The average life expectancy in Russia is 72.6 years Belgium is 81.6 years.Russians are in poorer health.

The Lancet study data suggests most people in the brilacidin study will also have coexisting conditions.It is also clear in the brilacidin trial patients with many medical conditions will not be excluded if they are medically stable. Managing the coexisting conditions is inherent to the trial.

GLTA,

Farrell